Brussels — 19 August 2024 — Capitalizing on the success of their joint collaboration this past January for 2024 Combination Products in the EU, DIA and the Regulatory Affairs Professionals Society (RAPS) are coming together once again to produce the 2024 Regulatory Policy Forum. This two-day, highly-interactive summit will convene 3-4 December at the Radisson Grand Place in Brussels to explore the new EU pharmaceutical legislation and how it will shape the future of the pharmaceutical arena—including research, development and manufacturing—in Europe for decades to come. 

“With the revision of its pharmaceutical legislation, the EU is currently going through a once in a generation landmark,” said Ania Mitan, Senior Vice President & Managing Director, EMEA and India, DIA. “This summit will unite trailblazers and pioneers across the field to examine how the availability, access and affordability of medicines is truly being addressed. These topics are critical to understand due to the significant impact they could have on keeping—and bringing—innovation to Europe and to patients.” 

Specifically for regulatory policy leaders, senior decision makers, and regulators across the pharmaceutical community, the 2024 Regulatory Policy Forum will highlight how the new legislation might alter the dynamics of the pharmaceutical ecosystem. Additionally, it will facilitate discussions that spark solutions and next steps towards a more vibrant and patient-centric pharmaceutical landscape. Topics to be explored include the concept of (high) unmet medical needs, ensuring competitiveness and innovation in Europe, how to make Europe a potential clinical trials hub, and the regulatory sandbox and other regulatory tools.

RAPS Executive Director Bill McMoil commented that “searching for solutions, stimulating collaboration, and addressing critical issues facing global regulatory professionals is at the forefront of RAPS’ mission and commitment to serve the profession. Working with DIA to develop programs like the 2024 Regulatory Policy Forum serves a timely and vital platform for professionals to talk through the impact of important legislative changes. I am excited by the broad endorsement from the leadership and membership of both organizations—as well as the profession at-large—for this program and look forward to seeing everyone in Brussels this December.”

The programme agenda is being curated by experts across the pharmaceutical community to ensure the highest quality discussions, knowledge exchange, and collaboration opportunities. Planning committee members to date include:

• Tamara Di Carlantonio, Regulatory Policy Lead, Roche
• Emma Du Four, Independent R&D/Regulatory Policy Professional
• Douglas Gregory, Senior Director, Government Affairs Strategy & Policy Advocacy, Bristol Myers Squibb
• Mercè Caturla Goñi, Head of Product Cluster, Regulatory Affairs Marketed Products Strategy (RAMP), Regulatory & Quality Affairs (RQA), Alexion Astra Zeneca Rare Disease, Barcelona
• Rebecca Lumsden, Head of Regulatory Science and Policy, EU/AMEE Region, Sanofi
• Nicky Wilson, Head of EMEA, Global Regulatory Policy & Intelligence, Johnson & Johnson
• European Medicines Agency (EMA) to be announced soon
• Heads of Medicines Agencies (HMA) to be announced soon

Registration is now open for the 2024 Regulatory Policy Forum. The complete programme agenda and speaker lineup will be announced in the coming weeks. To learn more, visit www.regpolicyforum.org.

Additionally, DIA and RAPS will again be jointly producing 2025 Combination Products in the EU on 28-29 January 2025 at the Radisson Grand Place in Brussels, Belgium. To learn more about that event, visit www.eucomboprods.org.